Results 1 to 10 of about 2,016 (108)

Neuroprotection by Ozanimod Following Intracerebral Hemorrhage in Mice

Frontiers in Molecular Neuroscience, 2022
The destruction of the blood-brain barrier (BBB) after intracerebral hemorrhage (ICH) is associated with poor prognosis. Modulation of sphingosine 1-phosphate receptor (S1PR) may improve outcomes from ICH.
Voon Wee Yong, Mengzhou Xue, Suliman Khan   +2 more
exaly   +3 more sources

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants [PDF]

Annals of Clinical and Translational Neurology
Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
doaj   +2 more sources

Efficacy and Safety of Ozanimod in Ulcerative Colitis: A Real-World Pan-Hellenic Study [PDF]

Medicina
Background and Objectives: Ozanimod is approved for the treatment of ulcerative colitis (UC). The aim of the present study was to evaluate the clinical, biochemical, and endoscopic outcomes.
Pavlos Pardalis, Alexandros Ioannou, Theodoros Delidis, Georgios Kokkotis, Georgios Leonidakis, Georgios Axiaris, Konstantinos Argyriou, Anthia Gatopoulou, Olga Giouleme, Nikolaos Kalakos, Pantelis Karatzas, Ioanna Nefeli Mastorogianni, Andreas Kapsoritakis, Efrosini Laoudi, Panagiotis Markopoulos, Konstantinos Katsanos, Georgios Michalopoulos, Konstantinos Mousourakis, Georgios Bamias, Georgios Papatheodoridis, Ioanna Papatzelou, Konstantinos Soufleris, Maria Tzouvala, Eftychia Tsironi, Ioannis Psaroudakis, Angeliki Theodoropoulou, Alexandra Varka, Nikos Viazis, Eirini Zacharopoulou, Konstantinos Karmiris, Ioannis Koutroubakis, Spyridon Michopoulos, Evanthia Zampeli   +32 more
doaj   +2 more sources

Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North Study [PDF]

Gastro Hep Advances
Background and Aims: Ozanimod is a once-daily, oral, selective sphingosine 1-phosphate receptor 1 and 5 modulator. The objective of the randomized, phase 2/3 J-True North study (NCT03915769) was to assess the efficacy and safety of ozanimod in Japanese ...
Hiroshi Nakase, Toshimitsu Fujii, Tadakazu Hisamatsu, Yasuo Suzuki, Mamoru Watanabe, Sakuma Takahashi, Makoto Ooi, Ken Takeuchi, Tsuguhiro Kimura, Ken Furuya, Nobuo Aoyama, Kenkei Hasatani, Noriyuki Horiki, Kazunari Kanke, Satoki Tokito, Souken Sai, Yoko Uchikawa, Shoichiro Goto, Go Fujimoto, Changliang Zhang, AnnKatrin Petersen, Toshifumi Hibi   +21 more
doaj   +2 more sources

Sphingosine-1-phosphate receptor modulators in ulcerative colitis – a narrative review of current evidence and practical considerations [PDF]

Drugs in Context
Ulcerative colitis (UC) is a chronic inflammatory bowel disorder with a relapsing and remitting course often necessitating the use of advanced therapy to maintain disease control. Sphingosine-1-phosphate receptor modulators (S1PRMs) represent a new class
Anish J Kuriakose Kuzhiyanjal, Karishma Sethi-Arora, Gaurav B Nigam, Jimmy K Limdi   +3 more
doaj   +2 more sources

Switch from fingolimod to ozanimod for safety or intolerance reasons [PDF]

Therapeutic Advances in Neurological Disorders
Introduction: Ozanimod is a new-generation sphingosine-1-phosphate (S1P) modulator, approved for the treatment of multiple sclerosis (MS), offering higher selectivity for S1P receptor 1 and 5 (SPR1-5), minimizing potential safety concerns related to S1P3
Elisabetta Signoriello, Giuseppe Romano, Matteo Foschi, Aurora Zanghì, Emanuele D’Amico, Roberta Fantozzi, Diego Centonze, Giacomo Lus   +7 more
doaj   +2 more sources

Case Report: Asymptomatic macular edema in ozanimod [PDF]

Frontiers in Ophthalmology
We report the case of a 61-year-old patient with relapsing–remitting multiple sclerosis (RRMS) who developed asymptomatic macular edema (ME) after initiation of ozanimod, a sphingosine-1-phosphate receptor (S1PR) modulator.
Valentina Annamaria Mauceri, Tommaso Torresin, Tommaso Torresin, Elisa Basili, Elisa Basili, Marta Gaggiola, Marta Gaggiola, Francesca Rinaldi, Francesco Baroni, Francesco Baroni, Paolo Gallo, Paolo Gallo, Paola Perini, Elisabetta Pilotto, Elisabetta Pilotto, Marco Puthenparampil, Marco Puthenparampil   +16 more
doaj   +2 more sources

A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application

Therapeutics and Clinical Risk Management, 2022
Noah Becher,1 Arun Swaminath,2 Keith Sultan3 1Department of Medicine, Hofstra/Northwell Health at Staten Island University Hospital, Staten Island, NY, USA; 2Division of Gastroenterology and Hepatology, Donald and Barbara Zucker School of Medicine at ...
Keith Sultan, Arun Swaminath
exaly   +2 more sources

Sphingosine-1-Phosphate (S1P) Receptor Modulators for the Treatment of Inflammatory Bowel Disease (IBD): Mechanisms, Clinical Evidence, and Practical Insights [PDF]

Biomedicines
Inflammatory bowel disease commonly requires advanced therapies to induce and maintain durable remission. Sphingosine-1-phosphate receptor modulators are the latest class of orally administered small molecules that have been added to the therapeutic ...
Natalie Shields, Michael Colwill, Valentina Raspa, Yaw Twum-Danso, Andrew Poullis, Kamal Patel, Sailish Honap   +6 more
doaj   +2 more sources

Extensive peripheral immunoglobulin repertoire analyses in people with multiple sclerosis reveal disease-specific signatures and distinct treatment effects of disease modifying drugs [PDF]

Journal of Neuroinflammation
Background B cells are crucial players in the pathogenesis of multiple sclerosis (MS), however, limited information is available on peripheral immunoglobulin (Ig) repertoires of people with MS (pwMS) in comparison to healthy individuals and during ...
Nicole Vasilenko, Christoph Ruschil, Josua Stadelmaier, Maria P. Tieck, Sonja Schembecker, Gregory P. Owens, Jeffrey L. Bennett, Achim Berthele, Ulf Ziemann, Sven Poli, Nicolas Snaidero, Sven Nahnsen, Mohamed A. Jarboui, Leon Bichmann, Gisela Gabernet, Markus C. Kowarik   +15 more
doaj   +2 more sources